Jeffrey Lancet, MD, discusses the findings from a phase III trial of CPX-351 versus 7+3 in older patients with high-risk, secondary acute myeloid leukemia
CPX-351: A Potential Game-Changer for Older Patients With Newly Diagnosed Secondary AML?
Recent Articles
AMA Delegates Pass Policy Recommendations to Equalize Gender Imbalances
The American Medical Association (AMA) approved several initiatives in an attempt to level the playing field for men and women in medicine. The recommendations...
Facebook Unveils U.S. Blood Donation Tool
Facebook has launched a blood donation feature on its U.S. platform to connect its users to donation centers in their neighborhoods and facilitate notifications...
House Overturns Trump Administration’s Fetal Tissue Research Ban
House lawmakers voted 225-193 on an amendment to overturn the Trump administration’s June 5 ban on federal funding for biomedical research involving human fetal...
Current Issue
June 2019, Volume 5, Issue 7
This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.
